Pro-Dex, Inc. (NASDAQ:PDEX - Free Report) - Ascendiant Capital Markets increased their Q2 2027 earnings per share estimates for Pro-Dex in a research note issued to investors on Sunday, November 15th. Ascendiant Capital Markets analyst E. Woo now anticipates that the medical instruments supplier will post earnings per share of $0.73 for the quarter, up from their prior forecast of $0.72. Ascendiant Capital Markets has a "Buy" rating and a $80.00 price target on the stock. The consensus estimate for Pro-Dex's current full-year earnings is $3.09 per share. Ascendiant Capital Markets also issued estimates for Pro-Dex's FY2027 earnings at $3.32 EPS, Q1 2028 earnings at $0.78 EPS, Q2 2028 earnings at $0.82 EPS, Q3 2028 earnings at $0.90 EPS, Q4 2028 earnings at $0.96 EPS and FY2028 earnings at $3.47 EPS.
A number of other brokerages also recently issued reports on PDEX. Zacks Research downgraded shares of Pro-Dex from a "strong-buy" rating to a "hold" rating in a research report on Monday, November 9th. Weiss Ratings raised shares of Pro-Dex from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, November 10th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $80.00.
Read Our Latest Stock Report on PDEX
Pro-Dex Stock Down 0.7%
NASDAQ:PDEX opened at $63.49 on Friday. Pro-Dex has a fifty-two week low of $29.29 and a fifty-two week high of $77.00. The stock has a market capitalization of $203.17 million, a P/E ratio of 17.52 and a beta of 0.12. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.49 and a current ratio of 4.19. The company's 50-day simple moving average is $64.91 and its 200-day simple moving average is $58.15.
Pro-Dex (NASDAQ:PDEX - Get Free Report) last announced its earnings results on Thursday, October 29th. The medical instruments supplier reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $20.56 million during the quarter, compared to the consensus estimate of $20.40 million. Pro-Dex had a net margin of 15.12% and a return on equity of 26.18%.
Insider Buying and Selling at Pro-Dex
In related news, CEO Kirk Richard Lee Van, Jr. sold 19,235 shares of the business's stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $60.58, for a total transaction of $1,165,256.30. Following the transaction, the chief executive officer directly owned 79,993 shares in the company, valued at $4,845,975.94. The trade was a 19.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Alisha Charlton sold 2,300 shares of the company's stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $61.30, for a total value of $140,990.00. Following the transaction, the chief financial officer directly owned 21,870 shares in the company, valued at $1,340,631. This represents a 9.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 22,300 shares of company stock worth $1,351,657. 48.00% of the stock is owned by company insiders.
Institutional Investors Weigh In On Pro-Dex
A number of large investors have recently modified their holdings of PDEX. James Investment Research Inc. purchased a new position in shares of Pro-Dex in the 3rd quarter valued at approximately $207,000. Focus Financial Network Inc. acquired a new stake in Pro-Dex in the 3rd quarter worth approximately $207,000. Navellier & Associates Inc. purchased a new stake in Pro-Dex during the 2nd quarter worth approximately $322,000. Ritholtz Wealth Management grew its position in Pro-Dex by 57.7% during the 3rd quarter. Ritholtz Wealth Management now owns 7,288 shares of the medical instruments supplier's stock worth $503,000 after purchasing an additional 2,668 shares during the last quarter. Finally, First Trust Advisors LP grew its position in Pro-Dex by 26.2% during the 3rd quarter. First Trust Advisors LP now owns 7,487 shares of the medical instruments supplier's stock worth $517,000 after purchasing an additional 1,553 shares during the last quarter. Hedge funds and other institutional investors own 15.28% of the company's stock.
About Pro-Dex
(
Get Free Report)
Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments and related accessories, with a focus on devices used in orthopedic procedures. Its products include surgical handpieces and drivers, along with the components and systems that support their operation. The company also provides engineering, product development and manufacturing services to medical device companies. Its work can span the product lifecycle, from design and prototyping to production and servicing. Founded in 1978, Pro-Dex is headquartered in Irvine, California, and serves customers in the United States and international markets.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pro-Dex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pro-Dex wasn't on the list.
While Pro-Dex currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.